Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 15;4:48. doi: 10.1038/s41420-018-0111-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Proliferation and differentiation of NSCs mediated by OA depends on the suppressing of the activation of GSK3β. a Western blot analyses and b relative optical density of diverse pathway markers including β-catenin (active), β-catenin, p-GSK3β (Ser9), and GSK3β in NSCs after treatment with OA for 7 days. *p < 0.05 and **p < 0.01, compared with the Ctr group; ^ap < 0.05, compared with 10 μM OA group. c Western blot analyses and d relative optical density of p-GSK3β (Ser9), GSK3β, p-GSK3β (Ser9), and GSK3β in NSCs after transfection with GSK3β (S9A) adenovirus for 2 days. **p < 0.01, compared with the Ad-Ctr group. e NSCs with GSK3β (S9A) significantly suppressed cell viability, as examined by CCK-8 assay. **p < 0.01, compared with Ad-Ctr + 20 μM OA group. f Western blot analyses and g relative optical density of diverse differentiation markers including Nestin, MAP2, and GFAP in NSCs transfected with GSK3β (S9A) treated with OA (20 μM). NSCs with GSK3β (S9A) significantly suppressed NSC neural differentiation. **p < 0.01, compared with Ad-Ctr + 20 μM OA group. All data are presented as means ± SD from three independent experiments